A novel small-molecule compound diaporine A inhibits non-small cell lung cancer growth by regulating miR-99a/mTOR signaling

References

• American Cancer Society. Cancer Facts and Figures. Atlanta, GA, American Cancer Society. 2012.
   Google Scholar
• Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009; 27:5848 - 56; http://dx.doi.org/10.1200/JCO.2009.24.0317; PMID: 19884536
   PubMed Web of Science ®Google Scholar
• Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med 2009; 60:167 - 79; http://dx.doi.org/10.1146/annurev.med.59.053006.104707; PMID: 19630570
   PubMed Web of Science ®Google Scholar
• Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005; 15:563 - 8; http://dx.doi.org/10.1016/j.gde.2005.08.005; PMID: 16099643
   PubMed Web of Science ®Google Scholar
• Palma CA, Al Sheikha D, Lim TK, Bryant A, Vu TT, Jayaswal V, Ma DD. MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia. Mol Cancer 2014; 13:79; http://dx.doi.org/10.1186/1476-4598-13-79; PMID: 24708856
   PubMed Web of Science ®Google Scholar
• Bertero T, Gastaldi C, Bourget-Ponzio I, Mari B, Meneguzzi G, Barbry P, Ponzio G, Rezzonico R. CDC25A targeting by miR-483-3p decreases CCND-CDK4/6 assembly and contributes to cell cycle arrest. Cell Death Differ 2013; 20:800 - 11; http://dx.doi.org/10.1038/cdd.2013.5; PMID: 23429262
   PubMed Web of Science ®Google Scholar
• Song Q, Xu Y, Yang C, Chen Z, Jia C, Chen J, Zhang Y, Lai P, Fan X, Zhou X, et al. miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM. Cancer Res 2014; 74:3031 - 42; http://dx.doi.org/10.1158/0008-5472.CAN-13-2193; PMID: 24710410
   PubMed Web of Science ®Google Scholar
• Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L, Kappeler A, Brunner T, Vassella E. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 2009; 69:5553 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-08-4277; PMID: 19549910
   PubMed Web of Science ®Google Scholar
• Wang Y, Gu J, Roth JA, Hildebrandt MA, Lippman SM, Ye Y, Minna JD, Wu X. Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res 2013; 73:4801 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-12-3273; PMID: 23774211
   PubMed Web of Science ®Google Scholar
• Bandi N, Vassella E. miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol Cancer 2011; 10:55; http://dx.doi.org/10.1186/1476-4598-10-55; PMID: 21575235
   PubMed Web of Science ®Google Scholar
• Yongchun Z, Linwei T, Xicai W, Lianhua Y, Guangqiang Z, Ming Y, Guanjian L, Yujie L, Yunchao H. MicroRNA-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB. Cancer Lett 2014; 347:65 - 74; http://dx.doi.org/10.1016/j.canlet.2014.01.019; PMID: 24486218
   PubMed Web of Science ®Google Scholar
• Oneyama C, Ikeda J, Okuzaki D, Suzuki K, Kanou T, Shintani Y, Morii E, Okumura M, Aozasa K, Okada M. MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene 2011; 30:3489 - 501; http://dx.doi.org/10.1038/onc.2011.63; PMID: 21383697
   PubMed Web of Science ®Google Scholar
• Gao W, Shen H, Liu L, Xu J, Xu J, Shu Y. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol 2011; 137:557 - 66; http://dx.doi.org/10.1007/s00432-010-0918-4; PMID: 20508945
   PubMed Web of Science ®Google Scholar
• Li Y, Kong D, Wang Z, Sarkar FH. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res 2010; 27:1027 - 41; http://dx.doi.org/10.1007/s11095-010-0105-y; PMID: 20306121
   PubMed Web of Science ®Google Scholar
• Sethi S, Li Y, Sarkar FH. Regulating miRNA by natural agents as a new strategy for cancer treatment. Curr Drug Targets 2013; 14:1167 - 74; http://dx.doi.org/10.2174/13894501113149990189; PMID: 23834152
   PubMed Web of Science ®Google Scholar
• Li Y, VandenBoom TG 2nd, Kong D, Wang Z, Ali S, Philip PA, Sarkar FH. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69:6704 - 12; http://dx.doi.org/10.1158/0008-5472.CAN-09-1298; PMID: 19654291
   PubMed Web of Science ®Google Scholar
• Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 2008; 7:464 - 73; http://dx.doi.org/10.1158/1535-7163.MCT-07-2272; PMID: 18347134
   PubMed Web of Science ®Google Scholar
• Tsang WP, Kwok TT. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J Nutr Biochem 2010; 21:140 - 6; http://dx.doi.org/10.1016/j.jnutbio.2008.12.003; PMID: 19269153
   PubMed Web of Science ®Google Scholar
• Sheth S, Jajoo S, Kaur T, Mukherjea D, Sheehan K, Rybak LP, Ramkumar V. Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PLoS One 2012; 7:e51655; http://dx.doi.org/10.1371/journal.pone.0051655; PMID: 23272133
   PubMed Web of Science ®Google Scholar
• Sun L, Hua C, Yang Y, Dou H, Li E, Tan R, Hou Y. Chaeoglobosin Fex inhibits poly(I:C)-induced activation of bone marrow-derived dendritic cells. Mol Immunol 2012; 51:150 - 8; http://dx.doi.org/10.1016/j.molimm.2012.02.125; PMID: 22424786
   PubMed Web of Science ®Google Scholar
• Yang Y, Dou H, Li X, Song Y, Gong W, Tan R, Hou Y. FC-98 regulates TLR9-mediated of CXCL-10 expression in dendritic cells via MAPK and STAT1 signaling pathway. Biomed Res Int 2014; 2014:926130; http://dx.doi.org/10.1155/2014/926130; PMID: 24696007
   PubMed Web of Science ®Google Scholar
• Hua C, Yang Y, Sun L, Dou H, Tan R, Hou Y. Chaetoglobosin F, a small molecule compound, possesses immunomodulatory properties on bone marrow-derived dendritic cells via TLR9 signaling pathway. Immunobiology 2013; 218:292 - 302; http://dx.doi.org/10.1016/j.imbio.2012.05.015; PMID: 22739238
   PubMed Web of Science ®Google Scholar
• Song Y, Dou H, Gong W, Liu X, Yu Z, Li E, Tan R, Hou Y. Bis-N-norgliovictin, a small-molecule compound from marine fungus, inhibits LPS-induced inflammation in macrophages and improves survival in sepsis. Eur J Pharmacol 2013; 705:49 - 60; http://dx.doi.org/10.1016/j.ejphar.2013.02.008; PMID: 23438875
   PubMed Web of Science ®Google Scholar
• Dou H, Song Y, Liu X, Yang L, Jiang N, Chen D, Li E, Tan R, Hou Y. A Novel Benzenediamine Derivate Rescued Mice from Experimental Sepsis by Attenuating Pro-inflammatory Mediators via IRAK4. Am J Respir Cell Mol Biol 2014; In press; http://dx.doi.org/10.1165/rcmb.2013-0411OC; PMID: 24588661
   PubMedGoogle Scholar
• Mori H, Kawai K, Ohbayashi F, Kuniyasu T, Yamazaki M, Hamasaki T, Williams GM. Genotoxicity of a variety of mycotoxins in the hepatocyte primary culture/DNA repair test using rat and mouse hepatocytes. Cancer Res 1984; 44:2918 - 23; PMID: 6722817
   PubMed Web of Science ®Google Scholar
• Igarashi Y, Kuwamori Y, Takagi K, Ando T, Fudou R, Furumai T, Oki T. Xanthoepocin, a new antibiotic from Penicillium simplicissimum IFO5762. J Antibiot (Tokyo) 2000; 53:928 - 33; http://dx.doi.org/10.7164/antibiotics.53.928; PMID: 11099226
   PubMed Web of Science ®Google Scholar
• Kawai KN. T.; Nozawa, Y. The biological activity of floccosin from Epidermophyton floccosum. The effects on mitochondrial reactions. Jpn J Assoc Mycotoxicol 1982; 16:1 - 3
   Google Scholar
• Tsutsui J, Kadomatsu K, Matsubara S, Nakagawara A, Hamanoue M, Takao S, Shimazu H, Ohi Y, Muramatsu T. A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms’ tumor and other human carcinomas. Cancer Res 1993; 53:1281 - 5; PMID: 8383007
   PubMed Web of Science ®Google Scholar
• Kerzerho J, Adotevi O, Castelli FA, Dosset M, Bernardeau K, Szely N, Lang F, Tartour E, Maillere B. The angiogenic growth factor and biomarker midkine is a tumor-shared antigen. J Immunol 2010; 185:418 - 23; http://dx.doi.org/10.4049/jimmunol.0901014; PMID: 20511550
   PubMed Web of Science ®Google Scholar
• Takei Y, Kadomatsu K, Matsuo S, Itoh H, Nakazawa K, Kubota S, Muramatsu T. Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 2001; 61:8486 - 91; PMID: 11731432
   PubMed Web of Science ®Google Scholar
• Zhao S, Zhao G, Xie H, Huang Y, Hou Y. A conjugate of an anti-midkine single-chain variable fragment to doxorubicin inhibits tumor growth. Braz J Med Biol Res 2012; 45:230 - 7; http://dx.doi.org/10.1590/S0100-879X2012007500009; PMID: 22267001
   PubMed Web of Science ®Google Scholar
• Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, Zamboni G, Maciejewski R. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma. BMC Cancer 2012; 12:369; http://dx.doi.org/10.1186/1471-2407-12-369; PMID: 22920721
   PubMed Web of Science ®Google Scholar
• Li D, Liu X, Lin L, Hou J, Li N, Wang C, Wang P, Zhang Q, Zhang P, Zhou W, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem 2011; 286:36677 - 85; http://dx.doi.org/10.1074/jbc.M111.270561; PMID: 21878637
   PubMed Web of Science ®Google Scholar
• Li XJ, Luo XQ, Han BW, Duan FT, Wei PP, Chen YQ. MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways. Br J Cancer 2013; 109:2189 - 98; http://dx.doi.org/10.1038/bjc.2013.562; PMID: 24030073
   PubMed Web of Science ®Google Scholar
• Sun D, Lee YS, Malhotra A, Kim HK, Matecic M, Evans C, Jensen RV, Moskaluk CA, Dutta A. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res 2011; 71:1313 - 24; http://dx.doi.org/10.1158/0008-5472.CAN-10-1031; PMID: 21212412
   PubMed Web of Science ®Google Scholar
• Cui L, Zhou H, Zhao H, Zhou Y, Xu R, Xu X, Zheng L, Xue Z, Xia W, Zhang B, et al. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. BMC Cancer 2012; 12:546; http://dx.doi.org/10.1186/1471-2407-12-546; PMID: 23173671
   PubMed Web of Science ®Google Scholar
• Jiang H, Qu L, Wang Y, Cong J, Wang W, Yang X. miR-99a promotes proliferation targeting FGFR3 in human epithelial ovarian cancer cells. Biomed Pharmacother 2014; 68:163 - 9; http://dx.doi.org/10.1016/j.biopha.2013.12.001; PMID: 24456664
   PubMed Web of Science ®Google Scholar
• Yen YC, Shiah SG, Chu HC, Hsu YM, Hsiao JR, Chang JY, Hung WC, Liao CT, Cheng AJ, Lu YC, et al. Reciprocal regulation of microRNA-99a and insulin-like growth factor I receptor signaling in oral squamous cell carcinoma cells. Mol Cancer 2014; 13:6; http://dx.doi.org/10.1186/1476-4598-13-6; PMID: 24410957
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926 - 45; http://dx.doi.org/10.1101/gad.1212704; PMID: 15314020
   PubMed Web of Science ®Google Scholar
• Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14:483 - 510; http://dx.doi.org/10.1146/annurev.immunol.14.1.483; PMID: 8717522
   PubMed Web of Science ®Google Scholar
• Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004; 279:2737 - 46; http://dx.doi.org/10.1074/jbc.M309999200; PMID: 14576155
   PubMed Web of Science ®Google Scholar
• Moschetta M, Reale A, Marasco C, Vacca A, Carratù MR. Therapeutic targeting of the mTOR-signaling pathway in cancer: benefits and limitations. Br J Pharmacol 2014; In press http://dx.doi.org/10.1111/bph.12749; PMID: 24780124
   PubMed Web of Science ®Google Scholar
• Beevers CS, Li F, Liu L, Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer 2006; 119:757 - 64; http://dx.doi.org/10.1002/ijc.21932; PMID: 16550606
   PubMed Web of Science ®Google Scholar
• Zhou H, Luo Y, Huang S. Updates of mTOR inhibitors. Anticancer Agents Med Chem 2010; 10:571 - 81; http://dx.doi.org/10.2174/187152010793498663; PMID: 20812900
   PubMed Web of Science ®Google Scholar
• Zhao G, Nie Y, Lv M, He L, Wang T, Hou Y. ERβ-mediated estradiol enhances epithelial mesenchymal transition of lung adenocarcinoma through increasing transcription of midkine. Mol Endocrinol 2012; 26:1304 - 15; http://dx.doi.org/10.1210/me.2012-1028; PMID: 22669742
   PubMed Web of Science ®Google Scholar